Price
Financials
Standalone, Rs crore| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 952 | 1,489 | 1,882 | 2,878 | 3,952 | 5,392 | 6,978 | 7,857 | 9,467 | 9,623 | 9,638 | 10,969 |
| Operating costs | 797 | 1,172 | 1,611 | 2,342 | 3,177 | 4,392 | 6,100 | 7,293 | 8,485 | 8,079 | 7,811 | 9,219 |
| EBITDA | 155 | 317 | 271 | 536 | 776 | 1,000 | 878 | 564 | 982 | 1,544 | 1,827 | 1,750 |
| EBITDA margin % | 16% | 21% | 14% | 19% | 20% | 19% | 13% | 7% | 10% | 16% | 19% | 16% |
| Depreciation & amortisation | 30 | 36 | 46 | 60 | 78 | 96 | 346 | 852 | 1,191 | 1,681 | 1,806 | 1,567 |
| Finance costs | 29 | 59 | 54 | 43 | 58 | 63 | 248 | 569 | 716 | 857 | 817 | 828 |
| Non-operating income | -357 | 35 | 129 | 185 | 28 | 12 | 843 | 923 | 619 | 357 | 505 | 296 |
| Pre-tax profit | -260 | 257 | 299 | 617 | 668 | 853 | 1,127 | 67 | -306 | -637 | -291 | -349 |
| Effective tax rate % | 15% | 26% | 29% | 25% | 30% | 39% | 25% | -99% | -56% | -26% | 14% | 17% |
| Profit after tax | -298 | 189 | 214 | 466 | 469 | 520 | 845 | 134 | -135 | -470 | -331 | -408 |
| Earnings per share (Rs) | -19.30 | 12.22 | 13.68 | 29.79 | 30.01 | 33.23 | 54.04 | 8.59 | -8.62 | -30.03 | -21.16 | -26.11 |
| Paid out as dividend % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | 22% | 9% | 5% | 14% | ||
| Profit CAGR | % | % | 0% | -19% | ||
| Share price CAGR | % | % | % | % | ||
| Average return on equity | 1% | -6% | -5% | -5% |
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net block (property, plant) | 476 | 613 | 858 | 1,153 | 1,355 | 1,800 | 6,220 | 6,010 | 10,809 | 10,138 | 9,076 | 7,948 |
| Capital work in progress | 115 | 148 | 133 | 77 | 110 | 131 | 1,021 | 941 | 805 | 762 | 367 | 328 |
| Investments | 232 | 232 | 177 | 262 | 245 | 54 | 156 | 163 | 0 | 0 | 0 | 0 |
| Current & other assets | 642 | 975 | 1,292 | 2,108 | 2,882 | 4,072 | 6,992 | 7,703 | 9,492 | 9,254 | 9,953 | 10,886 |
| Total assets | 1,465 | 1,968 | 2,461 | 3,601 | 4,592 | 6,057 | 14,389 | 14,817 | 21,106 | 20,154 | 19,395 | 19,162 |
| Share capital | 31 | 31 | 31 | 31 | 31 | 31 | 37 | 38 | 49 | 49 | 49 | 49 |
| Reserves & surplus | 649 | 847 | 1,121 | 1,602 | 1,822 | 2,455 | 4,142 | 4,675 | 6,777 | 8,064 | 7,646 | 7,126 |
| Total debt | 443 | 648 | 612 | 836 | 1,212 | 1,800 | 6,627 | 6,974 | 10,950 | 9,283 | 8,555 | 8,582 |
| Other liabilities & provisions | 341 | 442 | 697 | 1,132 | 1,526 | 1,769 | 3,583 | 3,130 | 3,331 | 2,758 | 3,146 | 3,405 |
| Equity + liabilities | 1,465 | 1,968 | 2,461 | 3,601 | 4,592 | 6,057 | 14,389 | 14,817 | 21,106 | 20,154 | 19,395 | 19,162 |
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 57 | 68 | 229 | 139 | 50 | 351 | 384 | 679 | 256 | 1,605 | 2,101 | 1,325 |
| Investing cash flow | -277 | -222 | -174 | -331 | -341 | -835 | -5,761 | -469 | -5,794 | -569 | -632 | -372 |
| Free cash flow (after capex) | -101 | -159 | -63 | -193 | -296 | -267 | -148 | 93 | -460 | 673 | 1,590 | 966 |
| Financing cash flow | 181 | 146 | -48 | 198 | 280 | 524 | 5,420 | -280 | 5,553 | -967 | -1,554 | -960 |
| Net change in cash | -39 | -8 | 7 | 6 | -11 | 40 | 44 | -70 | 16 | 70 | -85 | -8 |
| Cash conversion (OCF / EBITDA) % | 48% | 32% | 113% | 53% | 25% | 65% | 77% | 132% | 29% | 105% | 116% | 76% |
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on capital employed % | 15% | 24% | 18% | 27% | 27% | 30% | 14% | 2% | 1% | 2% | 3% | 3% |
| Receivable days | 88 | 120 | 94 | 71 | 97 | 86 | 118 | 99 | 121 | 137 | 137 | 122 |
| Inventory days | 240 | 195 | 252 | 253 | 229 | 223 | 243 | 289 | 289 | 267 | 311 | 311 |
| Payable days | 166 | 139 | 142 | 155 | 151 | 144 | 159 | 150 | 140 | 121 | 167 | 156 |
| Cash cycle (days) | 163 | 177 | 205 | 169 | 175 | 164 | 203 | 239 | 270 | 283 | 281 | 278 |
| Working capital days | 131 | 149 | 132 | 131 | 133 | 145 | 165 | 207 | 226 | 235 | 245 | 235 |
Fundamentals
Market value₹ Cr.
Last price₹
Book value / share₹
Return on capital3.07 %
Return on equity-5.35 %
Dividend yield%
Face value₹ 2.00
Revenue CAGR (TTM)14%
Profit CAGR (TTM)-19%
Standalone figures.
Valuation
Market capRs 5,093 Cr
Enterprise valueRs 13,591 Cr
Price to book0.71x
Price to sales0.46x
EV / EBITDA6.64x
EV / EBIT28.36x
EV / sales1.24x
Price to cash flow3.84x
Earnings yield-8.02%
Profitability
Operating margin (excl. other income)15.96%
Operating margin (incl. other income)18.66%
EBITDA margin18.66%
Pre-tax margin-3.18%
Net profit margin-3.72%
ROE-5.49%
ROCE2.99%
ROA-2.12%
ROE, 3-year average-5.32%
ROCE, 3-year average2.46%
ROA, 3-year average-2.02%
ROE, 5-year average-3.06%
ROCE, 5-year average3.16%
ROA, 5-year average-1.18%
ROIC (approx.)3.58%
Tax rate-17.14%
Other income / net worth4.13%
Growth
Sales growth (latest year)13.81%
Sales CAGR, 3 years5.03%
Sales CAGR, 5 years9.47%
Per share
EPS (TTM)Rs -16.77
EPS (latest year)Rs -16.77
EPS, 3-year averageRs -16.55
EPS, 5-year averageRs -9.62
Book value per shareRs 294.65
Sales per shareRs 450.45
Cash flow per shareRs 54.40
Efficiency
Asset turnover0.57x
Fixed asset turnover1.38x
Inventory turnover1.34x
Inventory days272 days
Debtor days122 days
Debtors turnover2.99x
Leverage
Total debtRs 8,582 Cr
Cash and bankRs 84 Cr
Net debtRs 8,498 Cr
Debt to equity1.20x
Net debt / EBITDA4.15x
Interest coverage0.58x
Owners' fund to total sources37.44%
Debt to assets44.79%
Cash flow
Operating cash flow (latest year)Rs 1,325 Cr
Investing cash flow (latest year)Rs -372 Cr
Financing cash flow (latest year)Rs -960 Cr
Net change in cash (latest year)Rs -8 Cr
Sales to cash flow8.28x
Statement figures
Net sales (TTM)Rs 10,969 Cr
Net sales (latest year)Rs 10,969 Cr
Operating profit excl. other income (latest year)Rs 1,750 Cr
Other income (TTM)Rs 296 Cr
EBITDA (TTM)Rs 2,046 Cr
PBDT (TTM)Rs 1,219 Cr
Profit before tax (TTM)Rs -349 Cr
Tax (latest year)Rs 60 Cr
Net profit (TTM)Rs -408 Cr
Net profit (latest year)Rs -408 Cr
Depreciation (TTM)Rs 1,567 Cr
Interest (TTM)Rs 828 Cr
Cost of goods sold (latest year)Rs 6,359 Cr
Total expenditure (latest year)Rs 9,219 Cr
Total income (latest year)Rs 11,265 Cr
Share capitalRs 49 Cr
ReservesRs 7,126 Cr
Shareholders' fundsRs 7,175 Cr
Total assetsRs 19,162 Cr
Net blockRs 7,948 Cr
Capital work in progressRs 328 Cr
InvestmentsRs 0 Cr
ReceivablesRs 3,670 Cr
InventoryRs 4,736 Cr
Other liabilitiesRs 3,405 Cr
Shares outstanding (crore)24.35
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | MATRIXLABS | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +0.3% | -2.8% | +3.1 pts |
| 1 month | +0.6% | -6.8% | +7.3 pts |
| 3 months | +16.6% | -7.6% | +24.2 pts |
| 6 months | +169.9% | +0.4% | +169.5 pts |
| 1 year | +40.6% | -9.9% | +50.5 pts |
| 2 years | -11.8% | -13.6% | +1.7 pts |
| 3 years | -23.5% | +14.2% | -37.7 pts |
Red flags
F-score 4 of 8| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2008-09-09 | Annual General Meeting | |
| 2007-07-09 | Agm | |
| 2006-09-18 | Agm/Div-Rs.1.20/- Per Sh |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Mylan Laboratories Ltd?
Mylan Laboratories Ltd (MATRIXLABS) has a market capitalisation of Rs Cr. at the 2009-08-13 close.